OTC dental products
Representatives for Vipont (Viadent), Pfizer (Plax) and Warner-Lambert (Listerine) met with FDA Chief Counsel Margaret Porter and other agency officials on April 20 to discuss whether "products intended for the treatment of plaque and similar conditions" are drugs or cosmetics, according to a memorandum of the meeting. The three companies have received reg and/or warning letters from FDA concerning plaque/gingivitis claims deemed by the agency to be drug claims. Drug Labeling Compliance Div. Director Richard Chastonay told a recent FDLI-sponsored meeting that FDA and industry may have reached an "impasse" on the OTC dental claims issue and that the agency may initiate legal actions.
You may also be interested in...
Biocon has made two key appointments to the management team of Biocon Biologics following a recent change in CEO for the biosimilars business.
The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.
Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.